Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Relmada Therapeutics Inc(RLMD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RLMD
10/20/2026: RLMD (2-star) is currently NOT-A-BUY. Pass it for now.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for central nervous system disorders, primarily major depressive disorder. Its main value driver is its lead asset, REL-1017, which aims to provide faster-acting relief than existing standard therapies. While the company has shown progress in advancing its pipeline, it remains a high-risk, speculative investment with no current commercial revenue. Key risks include intense competition from large pharmaceutical firms, the binary outcomes of clinical trials, and potential share dilution from future financing. The stock may suit growth-oriented investors with high risk tolerance who are looking for exposure to potential breakthroughs in psychiatry.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward growth potential tied to clinical binary events. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunity during periods of positive clinical data releases or favorable regulatory news. |
| Value investor | Weak fit | The company lacks stable earnings or cash flow, making standard value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay a dividend and has no near-term plans to initiate one. |
| Low-risk investor | Weak fit | The inherent risks of clinical-stage biotech development create high volatility unsuitable for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are susceptible to sharp price swings based on trial data and regulatory updates. |
| Valuation risk | Medium / high | Valuations are highly speculative as they are based on future potential rather than current profits. |
| Competition risk (CNS drug market) | High | The company competes with deep-pocketed pharmaceutical companies for market share in the antidepressant space. |
| Business quality | Medium | While the science is promising, the company is still early in proving commercial viability. |
| Dividend income | Low / none | Investors should not expect income generation from this stock. |
| Execution risk | High | Success depends entirely on the outcome of complex and expensive clinical trials. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 48.79% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/20/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 337.08M USD | Price to earnings Ratio - | 1Y Target Price 10.75 |
Price to earnings Ratio - | 1Y Target Price 10.75 | ||
Volume (30-day avg) 1.3M shares | Beta 0.51 | 52 Weeks Range 1.98 - 8.00 | Updated Date 10/20/2026 |
52 Weeks Range 1.98 - 8.00 | Updated Date 10/20/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Clinical stage research and development of pharmaceutical assets. | The company currently has no revenue-generating products and spends money to research and test potential new drugs. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 185.48M | Price to Sales(TTM) 9001.9 |
Enterprise Value 185.48M | Price to Sales(TTM) 9001.9 | ||
Enterprise Value to Revenue 7110.5 | Enterprise Value to EBITDA 0.54 | Shares Outstanding 106.67M | Shares Floating 82.64M |
Shares Outstanding 106.67M | Shares Floating 82.64M | ||
Percent Insiders 3.23 | Percent Institutions 94.68 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.